Hear how Sanofi is using conversational AI to deliver instant, compliant answers to patients and uncover real-world customer questions to identify content gaps and refine marketing strategies.
A top 100 biopharma shares how they improved their website for bladder cancer patients, delivering better care and driving 5x faster access to key resources.
Announcing Falcon Router, an agent to identify and route potential safety adverse event reports, product quality complaints, and medical inquiries.
Learn about Veeva Ostro’s conversational AI platform and features, and how to increase patient and HCP engagement with compliant, personalized conversations.
Across three visual specialties, machines are finding abnormalities faster and remembering change over time, shifting doctors toward treatment strategy.
Hear how Ferring Pharmaceuticals transformed a static digital experience with conversational AI to deliver instant answers and capture actionable Commercial Evidence that helps identify treatment barriers.
Hear how Takeda turned static website interactions into instant, compliant conversations and drives high-value actions, including requests for rep conversations, with Veeva Ostro.
Ostro has been recognized as a top workplace based on employee survey feedback evaluating culture, trust, and leadership.
The world's most popular digital channels center on intuitive search and chat functionality. Here’s how biopharmas can do the same.
Hear how Pacira moved past basic website metrics to uncover real-time user intent. By understanding user questions, Pacira optimized its digital content strategy.
See how to deliver instant answers on brand sites and email with Veeva Ostro's 100% compliant, conversational AI.
By providing patients and HCPs with instant, compliant answers and helping reps capture deeper context, teams can overcome treatment barriers and reach more patients.
Clinical teams have long used real world evidence to understand how a drug works. Now commercial teams can mine evidence from unstructured data to drive action.
Key Takeaways from 2026 Veeva Commercial Summit
Veeva Commercial Summit highlighted the latest agentic commercial innovations helping to bring more medicines to patients faster.
Learn about how leading brands are replacing static sites with conversational AI.
See how Veeva Ostro delivers instant answers for patients and HCPs with 100% compliant, conversational AI.
Jeff Leiden, M.D. and Chase Feiger, M.D. discuss the development of Journavx and a new model for accelerating drug innovation.
In the opening keynote at Veeva Summit, CEO Chase Feiger shares how Veeva Ostro’s precision AI provides instant answers for patients and HCPs and commercial evidence for brands.
OpenAI just announced a new product for physicians and healthcare providers. But Amazon, Google, and other players are taking it a step further.
Personalization and omnichannel marketing have dominated biopharma brand strategy for years, yet most brands have little to show for it.
Learn about the latest strategies and solutions for orchestrating continuous conversations across all touchpoints. Discover how to maintain context, enable two-way compliant dialogue, automatically coordinate intelligent responses, and more.
For decades, the ‘shots on goal’ model has driven up R&D costs while failing to deliver results. Vertex Pharmaceuticals just proved there’s a better way.
Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the acquisition of Ostro.
Veeva Systems (NYSE: VEEV) today announced the acquisition of Ostro, the leading brand engagement platform for life sciences.
Veeva is acquiring agentic AI company Ostro for $100 million to boost its AI capabilities for healthcare providers and patients.
Ostro co-founder Ahmed Elsayyad explains how pharma marketers can earn attention by simplifying complexity, using engaging formats, and aligning content with audience needs in a crowded digital landscape.
AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.
The latest DHC Group Point of View tackles the practical implications head-on with exclusive new HCP research powered by Sermo and perspectives from Fullspan Health, Ostro, Perform Media, and HealthCentral.
Transform a generic brand.com into personalized experiences for a complex psychiatric treatment with Ostro Sites for Patients.
The proposal shifts subsidies to HSAs and mandates transparency, yet industry leaders warn that vague policies may not lower premiums.
The article explores governance, risk, and compliance challenges healthcare organizations face when adopting large language models.
These founders took some blunt feedback, and used it as fuel to transform their startup.
Ostro's Head of Product, Gurjeev Singh, reveals how AI architecture delivers 10X engagement lifts and 200% prescription increases.
From CES surprises to readers’ 2026 bingo cards, STAT’s AI Prognosis explores predictions for health AI, from billing and regulation to AI doctors, drugs, lawsuits, and backlash.
Ostro and Havas earned a Guinness World Records title, gaining lessons in branding, collaboration, education, verification, and teamwork.
This year’s collection of 12 honorees separated themselves by dedicating resources to employee well-being and developing even stronger work environments to sustain culture.
This annual award celebrates the exceptional achievements and contributions of companies that have made a profound impact on their industries.
Ostro’s health AI literacy course set a Guinness World Record this week, with 698 participants completing the 30-minute online lesson in 24 hours.
Ostro and Havas earned a Guinness World Records certificate for the most users to take an online AI health literacy lesson in 24 hours.
Ostro and Havas Health Network have been granted a Guinness World Record for the most users to take an online artificial intelligence in health literacy lesson in 24 hours.
MM+M’s latest eBook explores how pharma brands can embrace AI to engage HCPs more effectively and become trusted partners by delivering relevant and meaningful content dynamically.
The U.S. will impose 100% tariffs on imported branded drugs from Oct. 1, 2025, exempting firms with U.S. projects. Pharma must localize, pursue deals, and manage unclear exemption rules.
Verily’s ex-chief commercial officer sued the healthtech company for wrongful employment, citing HIPAA violations.
How one oncology brand uses Ostro Sites for HCPs to drive high‑value HCP actions
The unified digital platform helps providers and patients access clear, compliant, and personalized pharmaceutical information with AI-powered tools.
The FDA has launched a two-pronged crackdown on drug ads, sending mass warnings to thousands of companies and secret cease-and-desist orders to 100 targeting specific promotions.
Ostro Health unveils a new engagement play, connecting pharma to HCPs faster.
The media company recently settled in the state of California, agreeing to pay a fine for sharing customer data to third-party advertisers.
Ostro's Airmark enables compliant, AI-driven conversations in pharma emails, boosting HCP engagement and system integration.
First-of-its-kind Solution Enables Real-Time HCP Engagement and Instant Responses Directly Within Email
Life-sciences digital engagement platform Ostro is launching an AI powered tool for healthcare providers to directly interact with pharmaceutical companies.
AI stocks fell on investor concerns, but experts see the drop as a needed correction that will separate hype from real value while supporting long-term growth.
Trump is pushing drugmakers to expand direct-to-consumer sales with MFN pricing, but industry leaders resist steep cuts and experts warn of risks to patient care.
A California jury found that Meta was “eavesdropping” in women’s health data. This decision has implications on the future of health privacy.
Fierce Pharma features Ostro’s analysis on why 65% of HCP digital interactions lead nowhere—and how AI-powered journey orchestration can change that.
Digital health leaders welcomed Trump’s AI Action Plan for promoting innovation through deregulation and data standards but flagged gaps in AI safety, patient consent, and regulatory oversight.
Industry leaders are bracing for Trump’s new reciprocal tariffs and the threat of steep biopharma duties that could disrupt global drug trade despite WTO rules.
Ostro is a 2025 Fierce Pharma Marketing Awards finalist in the "New Brand Launch" category for its work on the Ostro x BridgeBio Attruby launch.
Ostro CEO Chase Feiger explains how regulatory compliance can serve as a strategic enabler, fostering trust and accelerating AI innovation in pharmaceutical development.
Big Pharma is adopting marketing tactics from pro athletes—such as personal branding, storytelling, and influencer-style engagement—to build trust and connect more authentically with patients.
Trump’s proposed megabill includes provisions that could boost the biotech industry, particularly by streamlining FDA approvals and expanding support for domestic biomanufacturing.
GLP-1 drugs like Ozempic are reshaping consumer behavior beyond food by disrupting industries such as retail, casinos, airlines, and fitness, prompting brands to rethink engagement strategies.
Donald Trump's 2024 campaign and potential second term could reshape U.S. healthcare policy, including deregulation, cost transparency, and the rollback of Biden-era initiatives.
Chase Feiger outlines four essential strategies—ensuring regulatory compliance, fostering explainable AI, aligning with real-world life‑sciences use cases, and building strong cross-functional teams—to successfully implement AI in life-sciences organizations.
Senators are pushing to regulate or limit direct-to-consumer pharmaceutical advertising, raising concerns in the industry that such actions could threaten its $2 billion R&D investment model.
President Donald Trump signed on May 12 an executive order, the Most-Favored-Nation (MFN) prescription drug pricing policy, aimed to cut some U.S. medicine prices to match lower ones abroad.
The FDA's Elsa AI tool represents a pivotal step in integrating generative AI to streamline drug review processes and modernize regulatory practices.
The FDA's rollout of the AI tool "Elsa" was a predictable milestone in its broader, strategic shift toward generative AI-driven efficiencies in drug review processes, signaling the start of deeper transformative changes across regulatory operations.
The FDA's new generative AI tool, Elsa, is now accelerating clinical protocol reviews by summarizing data, identifying priorities, and streamlining workflows–marking a significant leap forward in regulatory review efficiency.
White Paper: Discover How Conversational AI Can Drive Engagement, Action, and Compliance for Your Brand
Havas today announced a strategic investment and partnership with Ostro, the trailblazing AI-powered engagement platform built for the life sciences industry
Ostro, the leading provider of AI-powered engagement solutions for life sciences, has filed a provisional U.S. patent application (US 19/036,907) titled "Machine Learning-Based Algorithms for Improved Generation of a Search Response."
Brand.com’s are connecting HCPs to information, with fewer hoops to jump through, courtesy of new digital tools promising to tee up personalized content.
Inside Chase Feiger's newest Forbes piece, he sits down with Giles Platford, President of the Takeda Plasma-Derived Therapies Business Unit, to discuss the challenges and breakthroughs shaping the future of PDTs.
Ostro, a leader in AI-driven digital engagement solutions, is proud to spotlight its partnership with the Desmoid Tumor Research Foundation (DTRF) as we approach Rare Disease Month, a meaningful time to foster awareness and champion impactful innovation.
How one oncology brand launched a complete patient support solution in two weeks.
AI can transform pharmaceutical marketing by scaling personalized content development and delivery and optimizing processes. But it must be deployed responsibly, with clear guardrails to ensure compliance.
As of October 1, 2024, pharmaceutical companies promoting prescription medicines in the UK must adhere to the revised standards outlined in the new Association of the British Pharmaceutical Industry (ABPI) 2024 Code of Conduct.
In the global fight against HIV, a twice-yearly injection could represent a seismic shift in prevention efforts.
The Healthcare Technology Report has recognized Ostro as one of the Top 100 Healthcare Technology Companies of 2024.
Is time spent on your website a sign of engagement or frustration? For pharma brands, recognizing the difference between productive and non-productive actions is crucial to driving meaningful engagement.
At Ostro, we don’t make new medicines, but we like to say that our talent is making medicine make sense.
The pharma sector faces a critical challenge: bridging the widening digital divide. To keep pace with rapid technological advancements, companies need to break down silos and integrate their digital initiatives, ensuring a seamless and effective approach to innovation.
As an industry, we owe it to our stakeholders—and most importantly, to the patients and providers that we support—to innovate and improve while remaining legally compliant.
On its 10th anniversary, Exact Sciences' Cologuard, a noninvasive, at-home alternative to colonoscopy, is a prime example of how consumerization can apply to diagnostics.
In this white paper, learn more about digital solutions that reduce administrative burdens and optimize efficiency so that HCPs can deliver better patient outcomes with more impactful results.
By actively addressing misinformation and meeting patients where they are in their patient journey, pharmaceutical companies not only protect their brand and reputation but also contribute to the broader goal of safeguarding public health.
How does a CEO transform a neuroscience-focused biopharma company into a pioneering leader in treating stigmatized conditions?
AI models transform data management, messaging, and content creation methods.
Can AI keep up its rapid pace of development? If you’re situationally aware, the answer is a resounding “yes.”
Learn how Dermavant is partnering with Ostro to use AI and high-touch engagement to elevate and personalize the patient journey.
If the past decade is any indication, the future for Vertex – and the patient communities it is seeking to support – looks promising indeed.
Access the report to view Ostro's impact and how our tech-enabled solutions can support your brand goals.
Discover how to implement a consumerized, technology-enabled digital approach to brand.com interactions by implementing a compliant, AI-powered Nurse Navigator solution.
Ostro's Navigate platform is reshaping pharmaceutical communications by putting people first.
We have an opportunity to fix these failures, together. And it starts with bringing consumerization to healthcare and pharma.
Exact Sciences in Forbes: An Innovative Approach to Consumerization
10 years ago, Christophe Weber became the first non-Japanese CEO in Takeda Pharmaceuticals’ 242 year history.
What role does serendipity play in forming a multi-billion dollar targeted oncology company?
Cofounder and CEO
Jazz Pharma's journey of improvisation to innovation
Jazz, a T50 Pharma, and unicorn among unicorns, thrives on a people-first culture. CEO Bruce Cozadd's mission-driven approach led to 11 therapeutics in 20 years.
In its fifth year, the 40 Under 40 program celebrates the industry’s most highly regarded young talent.
Startups have struggled in digital health but LLMs have the potential to unlock growth and disruption.
When designing a website for today’s consumers, it’s widely accepted that user experience and ease of navigation are critical.
Life sciences companies have the power to improve the health literacy of consumers.
Healthcare professionals (HCPs) want a more personal touch from pharma
Prestigious international awards program recognizes standout digital health and medical technology products and companies
Keeping the attention of your TV and print ad viewers is the key to maximizing your marketing funnel
Leading healthcare engagement platform looks back on banner year
Technology partnership aims to increase engagement by educating consumers about CooperSurgical’s Paragard
Leading healthcare engagement platform announces new name and visual identity
Chase Feiger, MD, spoke to Forbes about Ostro's Series B funding.
Ostro, recently rebranded from RxDefine, is getting an e-commerce makeover and $45 million in Series B funding…
Ostro co-founder and president named on prestigious healthcare list.
Marketing has always played an important role in driving HCP awareness, which was a critical foundation that the sales team would then grow into 1:1 relationships…
When it comes to marketing a pharmaceutical, medical device, or digital therapeutic, brand managers know that raising awareness is key…
This is the second in a two-part series about how life science brands are thinking about telehealth…
There are a lot of resources out there that address the pros and cons of telehealth, but they mostly focus on answering that question for clinicians. What about life sciences companies…
I've had many conversations with marketing leaders across pharmaceutical, medical device, and diagnostic companies around what the future of life science marketing looks like in the digital age…
Ostro CEO, Chase Feiger, discusses the three key elements of a successful patient engagement strategy.
Traditional patient-support programs must adapt to the new normal.
